{
    "id": 3068,
    "fullName": "PIK3CA I391M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA I391M lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). The functional effect of I391M is conflicting, as it demonstrates kinase activity similar to wild-type Pik3ca (PMID: 20530683), however in another study, results in increased cell proliferation and cell viability as compared to wild-type Pik3ca, in one of two different cell lines (PMID: 29533785), and therefore, its effect on Pik3ca protein function is unknown.",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 1863,
                    "pubMedId": 20530683,
                    "title": "Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20530683"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "I391M",
    "createDate": "02/11/2015",
    "updateDate": "02/21/2020",
    "referenceTranscriptCoordinates": {
        "id": 171906,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179209622A>G",
        "cDna": "c.1173A>G",
        "protein": "p.I391M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11051,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a uterine cancer patient harboring PIK3CA I391M demonstrated stable disease when treated with Rapamune (sirolimus) (PMID: 28514312).",
            "molecularProfile": {
                "id": 2891,
                "profileName": "PIK3CA I391M"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 363,
                "name": "uterine cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",
            "molecularProfile": {
                "id": 25949,
                "profileName": "ERBB2 pos PIK3CA I391M"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA I391M and PIK3R1 M326I (reported as M56I) was sensitive to Miransertib (ARQ092), demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 27335,
                "profileName": "PIK3CA I391M PIK3R1 M326I"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2891,
            "profileName": "PIK3CA I391M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25949,
            "profileName": "ERBB2 pos PIK3CA I391M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27335,
            "profileName": "PIK3CA I391M PIK3R1 M326I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171905,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179209622A>G",
            "cDna": "c.1173A>G",
            "protein": "p.I391M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171907,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179209622A>G",
            "cDna": "c.1173A>G",
            "protein": "p.I391M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171906,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179209622A>G",
            "cDna": "c.1173A>G",
            "protein": "p.I391M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}